Product Details
| Product Name:
FCPR03 |
CAS No.:
1917347-65-9 |
| Purity:
99.94% |
Supply Ability:
10g |
| Release date:
2026/05/11 |
Product Introduction
Bioactivity
| Name | FCPR03 |
| Description | FCPR03 is a selective inhibitor of phosphodiesterase 4 (PDE4) with IC50s of 31 nM, 47 nM, and 60 nM for PDE4B1, PDE4D7, and PDE4 catalytic domain, respectively. FCPR03 has neuroprotective, anti-inflammatory, and antidepressant-like effects. |
| In vitro | FCPR03 displays at least 2100-fold selectivity over other PDEs (PDE1-3 and PDE5-11). In HT-22 cells, FCPR03 (5, 10, and 20 μM) increases cell viability under the oxygen-glucose deprivation (OGD) induced condition in a dose-dependent manner. FCPR03 (20 μM) increases the levels of phosphorylated AKT, GSK-3β, and β-catenin. FCPR03 (20 μM) protects against OGD-induced cellular apoptosis in both HT-22 cells and cortical neurons. The levels of mitochondrial membrane potential (MMP) and ROS are restored by FCPR03. FCPR03 (10 μM) shows significant protective effects[2]. |
| In vivo | In adult male Sprague-Dawley rats following cerebral ischemia-reperfusion, FCPR03 increases the levels of phosphorylated AKT, GSK3β and β-catenin within the ischemic penumbra. In rats following MCAO, FCPR03 (1.25, 2.5, 5 mg/kg; i.p.) reduces the infarct volume and improves neurobehavioral outcomes[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 95 mg/mL (317.4 mM), Sonication is recommended.
|
| Keywords | β-catenin | stroke | Phosphodiesterase (PDE) | PDE4D7 | PDE4B1 | PDE4 | neuroprotective | ischemic | Inhibitor | inhibit | GSK3β | FCPR-03 | FCPR03 | FCPR 03 | anti-inflammatory | antidepressant-like | AKT |
| Inhibitors Related | Balipodect | Theophylline monohydrate | D(+)-Raffinose pentahydrate | Theobromine | Apremilast | Isoprenaline hydrochloride | Indomethacin | Icariin | Theophylline | Vardenafil hydrochloride | Sildenafil citrate | Doxofylline |
| Related Compound Libraries | Bioactive Compound Library | Antidepressant Compound Library | Multi-Target Compound Library | Neuroprotective Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Metabolism Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States